Relationships between protein C, protein S, von Willebrand factor and euglobulin lysis time and cardiovascular risk factors in subjects with and without coronary heart disease

Atherosclerosis

Volumn 140, Issue 1, 1998, Pages 55-64

  Dart, Anthony M ^a   Cooper, Bridget ^a   Kay, Sally B ^a   Salem, Hatem ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b BOX HILL HOSPITAL   (Australia)

Author keywords

Coronary heart disease; Euglobulin lysis time; Glucose; Insulin; Low density lipoprotein particle size; Protein C; Protein S; Triglyceride; Von Willebrand factor

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; PROTEIN C; PROTEIN S; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS; VASCULAR ENDOTHELIUM;

AGED; CORONARY DISEASE; EXERTION; FEMALE; HUMANS; HYDROLYSIS; MALE; MIDDLE AGED; PROTEIN C; PROTEIN S; RISK FACTORS; SERUM GLOBULINS; VON WILLEBRAND FACTOR;

EID: 0032171447     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00109-9     Document Type: Article

References (44)

1. Cox D.A., Vita J.A., Treasure C.B., Fish R.D., Alexander R.W., Ganz P., Selwyn A.P. Atherosclerosis impairs flow-mediated dilatation of coronary arteries in humans. Circulation. 80:1989;458-465.
2. Egashira K., Inou T., Hirooka Y., Yamada A., Maruoka Y., Kai H., Sugimachi M., Suzuki S., Takeshito A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 91:1993;29-37.
3. Vita J.A., Treasure C.B., Nabel E.G., Mc Lenachan J.M., Fish R.D., Yeung A.C., Vekshtein V.I., Selwyn A.P., Ganz P. Coronary vasomotor responses to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
4. Zeiher A.M., Drexler H., Wollschlager H., Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of atherosclerosis. Circulation. 83:1991;391-401.
5. Kugiyama K., Yasue H., Okumura K., Ogawa H., Fujimoto K., Nakao K., Yoshimura M., Motoyama T., Inoke Y., Kawano H. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation. 94:1996;266-272.
6. Andrews T.C., Ruby K., Barry J., Naimi C.L., Allred E., Ganz P., Selwyn A.P. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 95:1997;324-328.
7. Lijnen HR, Collen D. Endothelium in haemostasis and thrombosis. Prog Cardiovasc Dis 1997;39:343-50.
8. Lip G.Y.H., Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorder? Cardiovasc Res. 34:1997;255-265.
9. Thompson S.G., Kienast J., Pyke S.D.M., Haverkate F., Van De Loo J.C.W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:1995;635-641.
10. Jansson J.-H., Nilsson T.K., Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 66:1991;351-355.
11. Schmitz-Huebner U., Thompson S., Balleisen L., Fechtrup C., Grosse-Heitmeyer W., Kirchhof B., Most E., Muller U.-S., Seiffert C., Seiffert D., Van De Loo J. Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. Br Heart J. 59:1988;287-291.
12. Hamsten A., Blomback M., Wiman B., Svensson J., Szamosi A., De Faire U., Mettinger L. Haemostatic function in myocardial infarction. Br Heart J. 55:1986;58-66.
13. Rick M.E. Protein C and protein S: vitamin K dependent inhibitors of blood coagulation. J Am Med Assoc. 263(5):1990;701-703.
14. Preissner K.T. Biological relevance of the protein C system and laboratory diagnosis of protein C and protein S deficiencies. Clin Sci. 78:1990;351-364.
15. The ARIC Investigators, Conlan M.G., Folsom A.R., Finch A., Davis C.E., Sorlie P., Marucci G., Wu K.K. Associations of factor VII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 70:1993;380-385.
16. EURODIAB IDDM Complications Study Group, Greaves M., Malia R.G., Goodfellow K., Mattock M., Stevens L.K., Stephenson J.M., Fuller J.H. Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM complications study. Diabetologia. 40:1997;698-705.
17. Endre T., Mattiasson I., Berntorp E., Berglund G., Hulthen U.L. Coagulation and fibrinolytic factors in normotensive hypertension-prone men. J Hypertens. 14:1996;629-634.
18. Woodward M., Lowe G.D.O., Rumley A., Tunstall-Pedoe H., Philippou H., Lane D.A., Morrison C.E. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 97:1997;785-797.
19. Mehta J., Mehta P., Lawson D.L., Soldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol. 9:1987;263-288.
20. Heinrich J., Schulte H., Schonfeld R., Kohler E., Assmann G. Association of variables of coagulation fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 73(3):1995;374-379.
21. Verheugt F.W.A., Wouter ten Cate J., Sturk A., Imandt L., Verhorst P.M.J., Van Eenige M.I., Verwey W., Roos J.P. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol. 59:1987;1075-1079.
22. Hamsten A, Walldius G, Szamosi A, Blomback M, De Faire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;330:3-8.
23. Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WRS, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;328:533-7.
24. Gray R.P., Yudkin J.S., Patterson D.L. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J. 69:1993;228-232.
25. Aznar J., Estelles A., Tormo G., Sapena P., Tormo V., Blanch S., Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 59:1988;535-541.
26. Hanken K., Speiser W., Ruf W., Thiel W., Schlepper M., Muller-Berghaus G. High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction. Ann Hematol. 67:1993;237-244.
27. Juhan-Vague I., Alessi M.C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 78(1):1997;656-660.
28. Wiman B. Plasminogen activator inhibitor I (PAI-I) in plasma: its role in thrombotic disease. Thromb Haemost. 74(1):1995;71-76.
29. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., Miller G.J. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 342:1993;1076-1079.
30. Estelles A., Tormo G., Aznar J., Espana F., Tormo V. Reduced fibrinolytic activity in coronary heart disease in basal conditions and after exercise. Thromb Res. 40:1985;373-383.
31. Pedersen O.D., Munkvad S., Gram J., Kluft C., Jespersen J. Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. Eur Heart J. 14:1993;785-789.
32. Dart A.M., Sherrard B., Salem H. Protein S von Willebrand factor and euglobulin lysis time as markers of coronary heart disease: evidence of altered endothelial synthetic function (letter). Ann Intern Med. 126:1997;89.
33. Sherrard B., Simpson H., Cameron J., Wahi S., Jennings G., Dart A. LDL particle size in subjects with previously unsuspected coronary heart disease: relationship with other cardiovascular risk markers. Atherosclerosis. 126:1996;277-287.
34. Dart A.M., Sherrard B., Simpson H.F. Influence of Apo E phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary disease. Atherosclerosis. 130:1997;161-170.
35. Zimmerman T.S., Ratnoff O.O., Powell A.E. Immunological differentiation of classic hemophilia (Factor VIII deficiency) and von Willebrand disease. J Clin Invest. 50:1971;244-254.
36. Heart and Stroke Facts Report. Canberra: National Heart Foundation of Australia, 1995.
37. Chin J.P.F., Dart A.M. Therapeutic restoration of endothelial function in hypercholesterolaemic subjects: effect of fish oils. Clin Exp Pharmacol Physiol. 21:1994;749-755.
38. IIbβ3) mediated by fibrinogen and glycoprotein Ib von Willebrand factor. J Biol Chem. 267:1992;11300-11306.
39. Weiss H.J., Hawiger J., Rugeri Z.M., Turitto V.T., Thiagarajan P., Hoffman T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest. 83:1989;288-297.
40. Wagner D.D. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 6:1990;217-246.
41. Gabazza E.C., Takeya H., Deguchi H., Sumida Y., Taguchi O., Murata K., Nakatani K., Yano Y., Mohri M., Sata M., Shima T., Nishioka J., Suzuki K. Protein C activation in NIDDM patients. Diabetologia. 39:1996;1455-1461.
42. Pankow J.S., Folsom A.R., Province M.A., Rao D.C., Eckfeldt J., Heiss G., Shahar E., Wu K.K. Family history of coronary heart disease and hemostatic variables in middle-aged adults. Thromb Haemost. 77(1):1997;87-93.
43. Conlan M.G., Folsom A.R., Finch A., Davis C.E., Sorlie P., Wu K.K. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 70(5):1993;762-767.
44. Caputo M., Mantini G., Floriani I., Ciceri M., Noseda A., Bonomo L. Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary epiaortic and peripheral occlusive arterial disease. Eur Heart J. 17:1996;1329-1336.